Note to Affiliate: This document is based on the November 2023 Irish SmPC, the August 2020 J Tube IFU, the March 2019 NJ Tube IFU, the August 2020 PEG IFU, the 2019 CADD Duodopa Patient Information Guide, and the February 2019 CADD Duodopa Pump Operator's Manual.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
People in this piece are models, not actual patients.
Duodopa (levodopa/carbidopa intestinal gel) is for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results1
People in this piece are models, not actual patients.
Because ON TIME is their time
Give patients with advanced Parkinson’s disease more ON TIME1
- Advanced Parkinson’s disease can lead to increased motor fluctuations and decreased quality of life,2 and a narrowing therapeutic window makes symptom control difficult with oral levodopa3
- Treatment strategies that provide a continuous flow of dopamine, and can thus mimic normal physiological dopamine stimulation, have potential to improve control of patients with advanced Parkinson’s disease3
You can offer your patients 16 hours of continuous dopaminergic stimulation (CDS) with Duodopa1,3
- Therapeutic plasma levels of levodopa are achieved within 1 hour of Duodopa initiation and maintained with significantly less variation vs oral levodopa4
Intra-subject variability in levodopa plasma concentration starting from hour 2 to hour 16 were low (13%).4 Treatment is usually administered during the patient’s awake period. If medically justified, Duodopa may be administered for up to 24 hours.1
- By providing continuous levodopa delivery over 16 hours, Duodopa can help improve symptom control in patients with advanced Parkinson’s disease3
THE DUODOPA SYSTEM
Duodopa [levodopa/carbidopa intestinal gel] provides continuous levodopa delivery via infusion of levodopa to the upper
small intestine over 16 hours*1
*Treatment is usually administered during the patient's awake period. If medically justified, Duodopa may be administered for up to 24 hours1
Watch time: 5 min; 50 sec
THE DUODOPA SYSTEM
Duodopa [levodopa/carbidopa intestinal gel] provides continuous levodopa delivery via infusion of levodopa to the upper
small intestine over 16 hours*1
*Treatment is usually administered during the patient's awake period. If medically justified, Duodopa may be administered for up to 24 hours1
Watch time: 5 min; 50 sec
I want to receive more information via a product specialist
References
- Duodopa (levodopa/carbidopa intestinal gel) SmPC; [insert current date]
- Santos-Garcia D et al. Parkinsons Dis 2020: 2020:7537924.
- Nyholm D. Parkinsonism Relat Disord 2007; 13(suppl):S13-S17.
- Nyholm D et al. AAPSJ 2013; 15(2):316-323.
